Max Nisen, Columnist

Regeneron's Eylea Protection Is Weakening

Another combo failure leaves its best-selling drug exposed to a Novartis threat.

November 27, 2017 at 3:45 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

It's not looking good for Eylea, Regeneron Pharmaceuticals Inc.'s best-selling medicine.

Earlier this month, Novartis AG reported strong trial results for a possible competitor to the blockbuster eye drug. And on Monday, Regeneron announced it was giving up trying to combine Eylea with another medicine -- an effort that might have helped defend against Novartis's entry.